Prior to surgery, the ovarian
mass usually has something
important to say.
Fortunately, we speak
fluent cyst.
How OVA1 Works
The OVA1 test combines 5 biomarkers, including:
- Beta-2 microglobulin and CA 125-II are both up-regulated
- apolipoprotein A1, Prealbumin, and transferrin are all down-regulated.
The addition of the 4 biomarkers to CA 125-II identify a high percentage of cancers missed by CA 125 alone. The immunoassay results of the individual OVA1 components are combined by a proprietary software algorithm called OvaCalc®. The clinical result is reported as a number that ranges from 0 to 10.
Guidelines for treating women with an ovarian mass1,2
Guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Society of Gynecologic Oncologists (SGO), and the National Comprehensive Cancer Network (NCCN) recommend that women with an ovarian mass that is suspicious for cancer be under the care of a gynecologic oncologist.
The Society of Gynecologic Oncologists (SGO) comments on OVA13
A press release from September 2009 issued by the Society of Gynecologic Oncologists recognized the importance of OVA1 stating that it "...may help healthcare providers better detect when referral to a gynecologic oncologist is indicated." [Full SGO statement]
12117 Bee Caves Road, Building III, Suite 100, Austin, TX 78738
For full intended use of OVA1® click here. | Vermillion, OVA1 and OvaCalc are registered trademarks of Vermillion, Inc.